|Bid||0.1000 x N/A|
|Ask||0.1200 x N/A|
|Day's range||0.1000 - 0.1150|
|52-week range||0.0390 - 0.1950|
|Beta (5Y monthly)||2.54|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The Imugene Limited ( ASX:IMU ) share price has had a bad week, falling 12%. But that doesn't change the fact that the...
LOS ALTOS, Calif. & SYDNEY, July 20, 2023--RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee. “Kim and Scott’s extensive strategic, financial and clinical expertis